LinkedIn
Facebook
H1 Results 2026
Press Release
30 July 2026
30 July 2026
H1 2026 Results
The recording of Ipsen’s H1 2026 Results Call is now available on demand.
Watch the recording
About Ipsen
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.
Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries, and our partnerships around the world, enable us to bring medicines to patients in more than 100 countries.
If you are experiencing difficulties registering for the investor and analyst conference call, please contact: khalid.deojee@ipsen.com
Key Contacts
Henry Wheeler
Vice President, Investor Relations
Khalid Deojee
Senior Manager, Investor Relations